1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Uterine Fibroids Disease Overview

3. Uterine Fibroids Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Uterine Fibroids Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Uterine Fibroids Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Uterine Fibroids companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Uterine Fibroids Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
COMPANIES
AAVogen Inc, Armgo Pharma Inc, Biophytis SA, Elevian Inc, Faraday Pharmaceuticals Inc , Immunoforge Ltd, Immusoft Corp, Keren Therapeutics, MYOS RENS Technology Inc, Neurotune AG, Novartis AG, Regeneron Pharmaceuticals Inc, Ridgeline Therapeutics LLC, Teijin Pharma Ltd

Companies mentioned
AbbVie Inc, Allergan Plc, Auritec Pharmaceuticals Inc, Bayer AG, BioSpecifics Technologies Corp, Context Therapeutics LLC, Evestra Inc, Gedeon Richter plc, Immunitor Inc, Kissei Pharmaceutical Co Ltd, Luye Pharma Group Ltd, Ogeda SA, Takeda Pharmaceutical Co Ltd, TiumBio Co Ltd